Prior guidance was $3.13B-$3.17B. Now sees adjusted EBITDA $470M-$480M vs. previous view $455M-$475M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer
- Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection
- EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names
- Exact Sciences price target raised to $70 from $60 at Piper Sandler